Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors
10.3760/cma.j.issn.0253-3766.2019.06.003
- VernacularTitle: 恶性骨肿瘤中程序性死亡蛋白1及其配体的临床研究进展
- Author:
Haifeng HUANG
1
;
Hua ZHU
2
;
Xianteng YANG
1
;
Xiaoyi GUO
2
;
Shanshan LI
3
;
Quan XIE
4
;
Xiaobin TIAN
5
;
Zhi YANG
2
Author Information
1. Department of Orthopaedics, Guizhou Provincial People′s Hospital, Guiyang 550002, China
2. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China
3. Department of Anesthesiology, Guizhou Provincial People′s Hospital, Guiyang 550002, China
4. College of Big Data and Information Engineering, Guizhou University, Guiyang 550025, China
5. Clinical Medical College of Guizhou Medical University, Guiyang 550025, China
- Publication Type:Review
- Keywords:
Programmed cell death protein 1, PD-1;
Programmed cell death-Ligand 1, PD-L1;
Bone neoplasms
- From:
Chinese Journal of Oncology
2019;41(6):410-414
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death receptor 1 (PD-1) and its ligand PD-L1 have been shown to play an important role in evading the immune system. In recent years, PD-1/PD-L1 blockade has shown significant clinical effects in many malignancies, including malignant melanoma, renal cell carcinoma, classic Hodgkin lymphoma, non-small cell lung cancer and so on. PD-1/PD-L1 signaling pathway has become a new target of immunotherapy in patients with malignant tumors. However, there are few researches on immunotherapy in malignant bone tumors, and the progress of clinical research on PD-1/PD-L1 remains to be elucidated. This review started from the mechanism of PD-1/PD-L1 signaling in tumor immunity, and analyzed the application prospect of PD-1/PD-L1 antibodies in malignant bone tumors. We hope to provide a theoretical basis for the treatment of malignant bone tumors based on PD-1/PD-L1 signaling pathway in China.
